Adhesion of human platelets to albumin is synergistically increased by lysophosphatidic acid and adrenaline in a donor-dependent fashion

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 5, 2006, Pages 359-368

  Eriksson, Andreas C ^a   Whiss, Per A ^a   Nilsson, Ulrika K ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Adrenaline; Albumin; Lysophosphatidic acid; Platelet adhesion; Synergism

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ALBUMIN; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA2 INTEGRIN; BETA3 INTEGRIN; COLLAGEN; CREATINE KINASE; CREATINE PHOSPHATE; FIBRONECTIN; GLUCOSE; INSULIN; LYSOPHOSPHATIDIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; SCAVENGER; YOHIMBINE;

ANTIBODY SPECIFICITY; ARTICLE; ATHEROSCLEROSIS; BLOOD DONOR; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE RICH PLASMA; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ALBUMINS; AUTOANTIBODIES; BLOOD DONORS; BLOOD PLATELETS; CELL ADHESION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPINEPHRINE; HUMANS; LYSOPHOSPHOLIPIDS; P-SELECTIN; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; YOHIMBINE;

EID: 33745412760     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000233366.18605.b2     Document Type: Article

References (44)

1. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta 2002; 1582:204-215.
2. Motohashi K, Shibata S, Ozaki Y, Yatomi Y, Igarashi Y. Identification of lysophospholipid receptors in human platelets: the relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate. FEBS Lett 2000; 468:189-193.
3. Pages C, Simon M, Valet P, Saulnier-Blache JS. Lysophosphatidic acid synthesis and release. Prostaglandins and other Lipid Mediators 2001; 64:1-10.
4. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291 (Pt 3):677-680.
5. Gennero I, Xuereb JM, Simon MF, Girolami JP, Bascands JL, Chap H, et al. Effects of lysophosphatidic acid on proliferation and cytosolic Ca++ of human adult vascular smooth muscle cells in culture. Thromb Res 1999; 94:317-326.
6. Dimsdale JE, Moss J. Plasma catecholamines in stress and exercise. JAMA 1980; 243:340-342.
7. Lechin F, van der Dijs B, Lechin A, Orozco B, Lechin M, Baez S, et al. Plasma neurotransmitters and cortisol in chronic illness: role of stress. J Med 1994; 25:181-192.
8. Wang JS, Cheng LJ. Effect of strenuous, acute exercise on alpha2-adrenergic agonist-potentiated platelet activation. Arterioscler Thromb Vasc Biol 1999; 19:1559-1565.
9. Goldstein DS. Plasma norepinephrine in essential hypertension. A study of the studies. Hypertension 1981; 3:48-52.
10. Muller JE. Circadian variation and triggering of acute coronary events. Am Heart J 1999; 137:S1-S8.
11. Stubbs PJ, Laycock J, Alaghband-Zadeh J, Carter G, Noble MI. Circulating stress hormone and insulin concentrations in acute coronary syndromes: identification of insulin resistance on admission. Clin Sci (Lond) 1999; 96:589-595.
12. Barnett DB, Swart SS, Nahorski SR, Cook N. Characterisation of human platelet adrenoceptors. Adv Exp Med Biol 1985; 192:97-108.
13. Kobilka BK, Matsui H, Kobilka TS, Yang-Feng TL, Francke U, Caron MG, et al. Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. Science 1987; 238:650-656.
14. Banga HS, Simons ER, Brass LF, Rittenhouse SE. Activation of phospholipases A and C in human platelets exposed to epinephrine: role of glycoproteins IIb/IIIa and dual role of epinephrine. Proc Natl Acad Sci U S A 1986; 83:9197-9201.
15. Steen VM, Holmsen H, Aarbakke G. The platelet-stimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost 1993; 70:506-513.
16. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A 1998; 95:8070-8074.
17. Nilsson UK, Svensson SP, Grenegard M. Synergistic activation of human platelets by lysophosphatidic acid and adrenaline. Haematologica 2002; 87:730-739; 739.
18. Haserück N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, et al. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 2004; 103:2585-2592.
19. Eriksson AC, Whiss PA. Measurement of adhesion of human platelets in plasma to protein surfaces in microplates. J Pharmacol Toxicol Methods 2005; 52:356-365.
20. Whiss PA, Andersson RGG, Srinivas U. Modulation of P-selectin expression on isolated human platelets by an NO donor assessed by a novel ELISA application [published erratum appears in J Immunol Methods 1997; 206:183]. J Immunol Methods 1997; 200:135-143.
21. Patel Y, Rahman S, Siddiqua A, Wilkinson JM, Kakkar VV, Authi KS. Functional characterization of PM6/13, a beta3-specific (GPIIIa/CD61) monoclonal antibody that shows preferential inhibition of fibrinogen binding over fibronectin binding to activated human platelets. Thromb Haemost 1998; 79:177-185.
22. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A 1999; 96:6931-6936.
23. Hjemdahl P, Larsson PT, Wallen NH. Effects of stress and beta-blockade on platelet function. Circulation 1991; 84:VI44-VI61.
24. Graft J, Klinkhardt U, Harder S. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators. Thromb Res 2004; 113:295-302.
25. Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets 1996; 7:125-137.
26. Tokumura A, Yoshida J, Maruyama T, Fukuzawa K, Tsukatani H. Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. Thromb Res 1987; 46:51-63.
27. Bergkvist M, Carlsson J, Oscarsson S. Surface-dependent conformations of human plasma fibronectin adsorbed to silica, mica, and hydrophobic surfaces, studied with use of Atomic Force Microscopy. J Biomed Mater Res A 2003; 64:349-356.
28. Kim J, Somorjai GA. Molecular packing of lysozyme, fibrinogen, and bovine serum albumin on hydrophilic and hydrophobic surfaces studied by infrared-visible sum frequency generation and fluorescence microscopy. J Am Chem Soc 2003; 125:3150-3158.
29. Baugh L, Vogel V. Structural changes of fibronectin adsorbed to model surfaces probed by fluorescence resonance energy transfer. J Biomed Mater Res A 2004; 69:525-534.
30. Smith EB, Staples EM. Distribution of plasma proteins across the human aortic wall-barrier functions of endothelium and internal elastic lamina. Atherosclerosis 1980; 37:579-590.
31. Stastny JJ, Fosslien E. Quantitative alteration of some aortic intima proteins in fatty streaks and fibro-fatty lesions. Exp Mol Pathol 1992; 57:205-214.
32. Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost 2002; 28:555-568.
33. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69:1691-1695.
34. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70:380-385.
35. Kahn NN, Sinha AK. Down regulation of alpha 2 adrenergic receptor numbers in platelets by insulin. Biochim Biophys Acta 1992; 1134:292-296.
36. Kambayashi J, Shinoki N, Nakamura T, Ariyoshi H, Kawasaki T, Sakon M, et al. Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res 1996; 81:85-90.
37. Varani K, Gessi S, Caiazza A, Rastelli G, Portaluppi F, Borea PA. Platelet alpha2-adrenoceptor alterations in patients with essential hypertension. Br J Clin Pharmacol 1999; 47:167-172.
38. Nakahashi TK, Kambayashi J, Nakamura T, Le SN, Yoshitake M, Tandon NN, et al. Platelets in nonresponders to epinephrine stimulation showed reduced response to ADP. Thromb Res 2001; 104:127-135.
39. Freeman K, Farrow S, Schmaier A, Freedman R, Schork T, Lockette W. Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. Am J Hypertens 1995; 8:863-869.
40. Santoso S, Kunicki T. Platelet receptor polymorphisms and thrombotic risk. Ital Heart J 2001; 2:811-815.
41. Selheim F, Froyset AK, Strand I, Vassbotn FS, Holmsen H. Adrenaline potentiates PI 3-kinase in platelets stimulated with thrombin and SFRLLN: role of secreted ADP. FEBS Lett 2000; 485:62-66.
42. 2+ and protein kinase C is the major factor in determining the level of secretion from human platelets. Biochem J 1993; 289 (Pt 1):277-282.
43. Reed GL. Platelet secretory mechanisms. Semin Thromb Hemost 2004; 30:441-450.
44. Lo B, Li L, Gissen P, Christensen H, McKiernan PJ, Ye C, et al. Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet alpha-granule biogenesis. Blood 2005; 106:4159-4166.